Reposted by Arnaud Jabet
Positive topline results from the Phase 3 #OASIS trial evaluating oral #olorofim for invasive #aspergillosis. The study met its primary endpoint. We are pleased to have contributed to patient enrollment in Cologne.
#ClinicalTrials #FungalInfections
f2g.com/press-releas...
f2g.com
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis | F2G.
The study achieved the primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% and for AmBisome® follo ...